Boobalan Pachaiyappan
Stock Analyst at Roth MKM
(0.07)
# 4,728
Out of 5,058 analysts
243
Total ratings
32.8%
Success rate
-14.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Boobalan Pachaiyappan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COYA Coya Therapeutics | Reiterated: Buy | $12 | $4.34 | +176.50% | 4 | Oct 15, 2026 | |
| CRVO CervoMed | Reiterated: Buy | $7 | $2.25 | +211.11% | 23 | Oct 13, 2026 | |
| NRSN NeuroSense Therapeutics | Downgraded: Hold | $60 → $3.5 | $3.17 | +10.41% | 7 | Oct 13, 2026 | |
| CAPR Capricor Therapeutics | Reiterated: Hold | $7 | $7.27 | -3.71% | 19 | Oct 6, 2026 | |
| SWX: NWRN Newron Pharmaceuticals S.p.A. | Rated: Buy | CHF 19.00 | CHF 8.19 | +131.99% | 1 | Oct 5, 2026 | |
| LBRX LB Pharmaceuticals | Downgraded: Hold | $37 → $35 | $36.71 | -4.66% | 6 | Oct 5, 2026 | |
| ABEO Abeona Therapeutics | Initiated Coverage: Buy | $17 | $4.65 | +265.59% | 1 | Sep 19, 2026 | |
| MNOV MediciNova | Initiated Coverage: Buy | $6 | $1.45 | +313.79% | 1 | Sep 19, 2026 | |
| ANVS Annovis Bio | Reiterated: Buy | $7 | $1.05 | +566.67% | 3 | Sep 4, 2026 | |
| OVID Ovid Therapeutics | Reiterated: Buy | $7 → $8 | $2.26 | +253.98% | 5 | Sep 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 → $29 | $7.10 | +308.45% | 6 | Sep 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $10 → $9 | $4.39 | +105.01% | 26 | Aug 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $30 → $29 | $8.70 | +233.33% | 3 | Aug 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $1.50 | +1,900.00% | 17 | Aug 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $1.33 | +501.50% | 29 | Aug 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $9 → $8 | $4.90 | +63.27% | 21 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $11 | $4.78 | +130.13% | 22 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $30 → $1 | $0.475 | +110.53% | 8 | Apr 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $11.82 | n/a | 11 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.5979 | n/a | 3 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.5373 | n/a | 2 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $41.47 | n/a | 9 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $8.90 | n/a | 5 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $18.74 | n/a | 6 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $0.3 | $12.20 | n/a | 5 | Sep 19, 2023 |
Coya Therapeutics
Oct 15, 2026
Reiterated: Buy
Price Target: $12
Current: $4.34
Upside: +176.50%
CervoMed
Oct 13, 2026
Reiterated: Buy
Price Target: $7
Current: $2.25
Upside: +211.11%
NeuroSense Therapeutics
Oct 13, 2026
Downgraded: Hold
Price Target: $60 → $3.5
Current: $3.17
Upside: +10.41%
Capricor Therapeutics
Oct 6, 2026
Reiterated: Hold
Price Target: $7
Current: $7.27
Upside: -3.71%
Newron Pharmaceuticals S.p.A.
Oct 5, 2026
Rated: Buy
Price Target: CHF 19.00
Current: CHF 8.19
Upside: +131.99%
LB Pharmaceuticals
Oct 5, 2026
Downgraded: Hold
Price Target: $37 → $35
Current: $36.71
Upside: -4.66%
Abeona Therapeutics
Sep 19, 2026
Initiated Coverage: Buy
Price Target: $17
Current: $4.65
Upside: +265.59%
MediciNova
Sep 19, 2026
Initiated Coverage: Buy
Price Target: $6
Current: $1.45
Upside: +313.79%
Annovis Bio
Sep 4, 2026
Reiterated: Buy
Price Target: $7
Current: $1.05
Upside: +566.67%
Ovid Therapeutics
Sep 3, 2026
Reiterated: Buy
Price Target: $7 → $8
Current: $2.26
Upside: +253.98%
Sep 1, 2026
Reiterated: Buy
Price Target: $19 → $29
Current: $7.10
Upside: +308.45%
Aug 24, 2026
Rated: Buy
Price Target: $10 → $9
Current: $4.39
Upside: +105.01%
Aug 21, 2026
Rated: Buy
Price Target: $30 → $29
Current: $8.70
Upside: +233.33%
Aug 19, 2026
Reiterated: Buy
Price Target: $30
Current: $1.50
Upside: +1,900.00%
Aug 18, 2026
Reiterated: Buy
Price Target: $8
Current: $1.33
Upside: +501.50%
Aug 14, 2026
Rated: Buy
Price Target: $9 → $8
Current: $4.90
Upside: +63.27%
Aug 12, 2026
Reiterated: Buy
Price Target: $10 → $11
Current: $4.78
Upside: +130.13%
Apr 1, 2026
Rated: Buy
Price Target: $30 → $1
Current: $0.475
Upside: +110.53%
May 20, 2024
Rated: Hold
Price Target: n/a
Current: $11.82
Upside: n/a
May 20, 2024
Rated: Hold
Price Target: n/a
Current: $0.5979
Upside: n/a
May 20, 2024
Rated: Hold
Price Target: n/a
Current: $0.5373
Upside: n/a
May 20, 2024
Rated: Hold
Price Target: n/a
Current: $41.47
Upside: n/a
May 20, 2024
Rated: Hold
Price Target: n/a
Current: $8.90
Upside: n/a
Oct 24, 2023
Reiterated: Hold
Price Target: n/a
Current: $18.74
Upside: n/a
Sep 19, 2023
Reiterated: Hold
Price Target: $0.3
Current: $12.20
Upside: n/a